Catalio Capital Management, Lp
SEC-registered
Private Fund Manager · Mid-sized ($1B–$10B)
CRD 310374
· SEC file 801-121976
· New York, NY
· www.linkedin.com
☆ Save with Pro
ADV data as of Mar 31, 2026
- Regulatory AUM
- $2.2B
- Discretionary
- $1.9B
- Clients
- 33
- Avg AUM / client
- $66.0M
- Accounts
- 33
- Employees
- 30
AUM over time
$250M
$2.2B
Jun 2021
Dec 2025
Annual snapshots from Form ADV filings · as of Mar 31, 2026
Investments (13F portfolio — 41 positions, $478,704,496)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Dianthus Therapeutics Inc | COM | $47,021,047 | 560,308 | 9.82% | 2.16% |
| 2 | Bridgebio Pharma Inc | COM | $32,081,360 | 432,014 | 6.7% | 1.47% |
| 3 | Ascendis Pharma A/S | SPONSORED ADR | $29,531,559 | 129,111 | 6.17% | 1.36% |
| 4 | Bristol Myers Squibb Co | COM | $25,517,093 | 420,727 | 5.33% | 1.17% |
| 5 | Syndax Pharmaceuticals Inc | COM | $24,380,131 | 1,043,670 | 5.09% | 1.12% |
| 6 | Gilead Sciences Inc | COM | $22,843,440 | 163,905 | 4.77% | 1.05% |
| 7 | Terns Pharmaceuticals Inc | COM | $21,564,114 | 409,031 | 4.5% | 0.99% |
| 8 | Definium Therapeutics Inc | COM SHS | $19,617,898 | 1,037,984 | 4.1% | 0.9% |
| 9 | Soleno Therapeutics Inc | COM | $19,345,012 | 577,808 | 4.04% | 0.89% |
| 10 | Boston Scientific Corp | COM | $18,782,205 | 299,318 | 3.92% | 0.86% |
| 11 | Ultragenyx Pharmaceutical In | COM | $17,824,197 | 850,797 | 3.72% | 0.82% |
| 12 | Incyte Corp | COM | $17,139,346 | 182,101 | 3.58% | 0.79% |
| 13 | Cytokinetics Inc | COM NEW | $14,203,671 | 215,501 | 2.97% | 0.65% |
| 14 | Natera Inc | COM | $14,180,691 | 70,907 | 2.96% | 0.65% |
| 15 | Corvus Pharmaceuticals Inc | COM | $13,048,980 | 891,933 | 2.73% | 0.6% |
| 16 | Structure Therapeutics Inc | SPONSORED ADS | $12,309,268 | 255,379 | 2.57% | 0.57% |
| 17 | Mineralys Therapeutics Inc | COM | $11,893,621 | 439,041 | 2.48% | 0.55% |
| 18 | Edwards Lifesciences Corp | COM | $11,580,129 | 144,607 | 2.42% | 0.53% |
| 19 | Veradermics Inc | COMMON STOCK | $10,961,703 | 173,582 | 2.29% | 0.5% |
| 20 | Adaptive Biotechnologies Cor | COM | $10,032,242 | 722,784 | 2.1% | 0.46% |
| 21 | Heartflow Inc | COM | $9,819,296 | 403,588 | 2.05% | 0.45% |
| 22 | Kalvista Pharmaceuticals Inc | COM | $8,586,472 | 426,551 | 1.79% | 0.39% |
| 23 | Uniqure Nv | SHS | $8,029,747 | 491,116 | 1.68% | 0.37% |
| 24 | Disc Medicine Inc | COM | $7,863,213 | 122,978 | 1.64% | 0.36% |
| 25 | Septerna Inc | COM | $7,073,471 | 294,360 | 1.48% | 0.32% |
Top 25 of 41 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Investment companies | 1 | $158M | 7.27% |
| Pooled investment vehicles (non-investment companies) | 26 | $1.4B | 65.2% |
| Pension and profit sharing plans | 1 | $31.5M | 1.45% |
| Charitable organizations | 1 | $46.4M | 2.13% |
| Other investment advisers | 2 | $250M | 11.5% |
| Corporations and other businesses | 1 | $47.3M | 2.18% |
| Other | 1 | $224M | 10.3% |
Private funds (15)
Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $1.0B combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Catalio Nexus Fund Iii, Lp | Private Equity Fund | Delaware | $365M | 327 |
| Catalio Nexus Fund Iv, Lp | Private Equity Fund | Delaware | $191M | 166 |
| Catalio Public Equities Master Fund, Lp master | Hedge Fund | Delaware | $109M | 59 |
| Catalio Nexus Fund Ii, Lp | Private Equity Fund | Delaware | $87.9M | 151 |
| Catalio Structured Opportunities Fund I Lp | Other Private Fund | Delaware | $54.5M | 83 |
| Catalio Genesis Fund I, Llc | Venture Capital Fund | Delaware | $46.8M | 54 |
| Catalio Genesis Fund Ii, Llc | Venture Capital Fund | Delaware | $43.4M | 100 |
| Catalio Genesis Fund Iii, Llc | Venture Capital Fund | Delaware | $35.8M | 77 |
| Catalio Structured Opportunities Aiv I Lp | Other Private Fund | Delaware | $30.7M | 80 |
| Catalio Access Fund V, Llc | Venture Capital Fund | Delaware | $15.5M | 60 |
| Catalio Genesis Fund Iv, Llc | Venture Capital Fund | Delaware | $11.3M | 51 |
| Catalio Nexus Fund I, Lp | Venture Capital Fund | Delaware | $9.3M | 58 |
| Catalio Access Fund Vi, Llc | Venture Capital Fund | Delaware | $8.3M | 36 |
| Catalio Access Fund I, Llc | Venture Capital Fund | Delaware | $5.3M | 44 |
| Catalio Special Opportunities Fund I, Llc | Venture Capital Fund | Delaware | $737K | 5 |
People (3)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Petrocheilos, Georgios, Nmn | Member | Jun 2020 (6y) | ≈ 0% – 3.75% via Catalio Capital Gp, Llc | |
| Vogelstein, Rachel, Jacob | Member | Jun 2020 (6y) | ≈ 0% – 3.75% via Catalio Capital Gp, Llc | |
| Maltseva, Olga, Eduardovna | Chief Compliance Officer And Head Of Operations | Jun 2021 (5y) | Less than 5% |
Entity owners (Schedule A/B)
| Entity | Title / status | Since | Sch. | Ownership |
|---|---|---|---|---|
| Stonebird Partners, Lp | Limited Partner | Jan 2023 | A | 50% – 75% |
| Kkr Catalina Holdings L.P. | Limited Partner | Oct 2023 | A | 25% – 50% |
| Catalio Capital Gp, Llc | General Partner | Jun 2020 | A | Less than 5% |
| Kkr Group Assets Holdings Ii L.P. | Limited Partner | Oct 2023 | B | ≈ 18.75% – 50% via Kkr Catalina Holdings L.P. |
| Kkr Group Partnership L.P. | Limited Partner | Oct 2023 | B | ≈ 14.06% – 50% via Kkr Group Assets Holdings Ii L.P. |
| Kkr Group Co. Inc. | Limited Partner | Oct 2023 | B | ≈ 2.64% – 25% via Kkr Group Holdings L.P. |
| Kkr & Co. Inc. | Shareholder | Oct 2023 | B | ≈ 1.98% – 25% via Kkr Group Co. Inc. |
| Kkr Group Holdings L.P. | Limited Partner | Oct 2023 | B | ≈ 3.52% – 25% via Kkr Group Partnership L.P. |
| Kkr Group Assets Gp Ii Llc | General Partner | Oct 2023 | B | GP / trustee / elected manager of Kkr Group Assets Holdings Ii L.P. (indirect) |
| Kkr Catalina Gp Llc | General Partner | Oct 2023 | B | GP / trustee / elected manager of Kkr Catalina Holdings L.P. (indirect) |
| Kkr Group Holdings Corp. | General Partner | Oct 2023 | B | GP / trustee / elected manager of Kkr Group Partnership L.P. (indirect) |
Undisclosed: 0% – 25% of the firm is not attributable from the filed Schedule A bands.
Estimated effective ownership (look-through of filed bands):
- Petrocheilos, Georgios, Nmn: 50% – 75% of Catalio Capital Gp, Llc × 0% – 5% direct ≈ 0% – 3.75% of the firm
- Vogelstein, Rachel, Jacob: 50% – 75% of Catalio Capital Gp, Llc × 0% – 5% direct ≈ 0% – 3.75% of the firm
- Kkr Group Assets Holdings Ii L.P.: 75% – 100% of Kkr Catalina Holdings L.P. × 25% – 50% direct ≈ 18.75% – 50% of the firm
- Kkr Group Partnership L.P.: 75% – 100% of Kkr Group Assets Holdings Ii L.P. × 75% – 100% of Kkr Catalina Holdings L.P. × 25% – 50% direct ≈ 14.06% – 50% of the firm
- Kkr Group Co. Inc.: 75% – 100% of Kkr Group Holdings L.P. × 25% – 50% of Kkr Group Partnership L.P. × 75% – 100% of Kkr Group Assets Holdings Ii L.P. × 75% – 100% of Kkr Catalina Holdings L.P. × 25% – 50% direct ≈ 2.64% – 25% of the firm
- Kkr & Co. Inc.: 75% – 100% of Kkr Group Co. Inc. × 75% – 100% of Kkr Group Holdings L.P. × 25% – 50% of Kkr Group Partnership L.P. × 75% – 100% of Kkr Group Assets Holdings Ii L.P. × 75% – 100% of Kkr Catalina Holdings L.P. × 25% – 50% direct ≈ 1.98% – 25% of the firm
- Kkr Group Holdings L.P.: 25% – 50% of Kkr Group Partnership L.P. × 75% – 100% of Kkr Group Assets Holdings Ii L.P. × 75% – 100% of Kkr Catalina Holdings L.P. × 25% – 50% direct ≈ 3.52% – 25% of the firm
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (15, $1.0B gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Catalio Nexus Fund Iii, Lp | Private Equity Fund | $365M | $500K | 327 |
| Catalio Nexus Fund Iv, Lp | Private Equity Fund | $191M | $1.0M | 166 |
| Catalio Public Equities Master Fund, Lp | Hedge Fund | $109M | $1.0M | 59 |
| Catalio Nexus Fund Ii, Lp | Private Equity Fund | $87.9M | $500K | 151 |
| Catalio Structured Opportunities Fund I Lp | Other Private Fund | $54.5M | $1.0M | 83 |
| Catalio Genesis Fund I, Llc | Venture Capital Fund | $46.8M | $500K | 54 |
| Catalio Genesis Fund Ii, Llc | Venture Capital Fund | $43.4M | $250K | 100 |
| Catalio Genesis Fund Iii, Llc | Venture Capital Fund | $35.8M | $250K | 77 |
| Catalio Structured Opportunities Aiv I Lp | Other Private Fund | $30.7M | $1.0M | 80 |
| Catalio Access Fund V, Llc | Venture Capital Fund | $15.5M | $250K | 60 |
| Catalio Genesis Fund Iv, Llc | Venture Capital Fund | $11.3M | $250K | 51 |
| Catalio Nexus Fund I, Lp | Venture Capital Fund | $9.3M | $250K | 58 |
| Catalio Access Fund Vi, Llc | Venture Capital Fund | $8.3M | $250K | 36 |
| Catalio Access Fund I, Llc | Venture Capital Fund | $5.3M | $250K | 44 |
| Catalio Special Opportunities Fund I, Llc | Venture Capital Fund | $737K | $350K | 5 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/31/2026 | 6.2 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for investment companies
- • Portfolio management for pooled investment vehicles
- • Portfolio management for businesses/institutional clients
Custody
Reported custodians
- Morgan Stanley $522M (24% of AUM) Mar 2026
- Bnp Paribas Ireland Unlimited Company $92.5M (4% of AUM) Mar 2026
- Goldman Sachs $20.9M (1% of AUM) Mar 2026
Amounts as reported in ADV Item 5.K.(3) (custodians holding 10%+ of SMA assets).
Firm reports having custody of client funds or securities (Item 9.A).
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 31, 2026.
View current Form ADV (SEC/IAPD) ↗